Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Nakatsuka, Atsuko ^a   Matsuyama, Makoto ^b   Yamaguchi, Satoshi ^a   Katayama, Akihiro ^a   Eguchi, Jun ^a   Murakami, Kazutoshi ^a   Teshigawara, Sanae ^a   Ogawa, Daisuke ^a   Wada, Nozomu ^a   Yasunaka, Tetsuya ^a   Ikeda, Fusao ^a   Takaki, Akinobu ^a   Watanabe, Eijiro ^c   Wada, Jun ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Shigei Medical Research Institute and Hospital   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN HEAVY CHAIN; PEMT PROTEIN, HUMAN; PEMT PROTEIN, MOUSE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PROTEIN P53;

ANIMAL; APOPTOSIS; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DOWN REGULATION; ENZYMOLOGY; GENE SILENCING; GENETIC PREDISPOSITION; GENETICS; HUMAN; LIPID DIET; LIVER CELL; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CLATHRIN HEAVY CHAINS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; HEPATOCYTES; HUMANS; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84962287490     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21721     Document Type: Article

References (53)

1. Asrih, M. & Jornayvaz, F. R. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol 418 Pt 1, 5565 (2015).
2. Margariti, E., Deutsch, M., Manolakopoulos, S. & Papatheodoridis, G. V. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol 25, 4551 (2012).
3. Bhat, G., Baba, C. S., Pandey, A., Kumari, N. & Choudhuri, G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop Gastroenterol 34, 1824 (2013).
4. Feng, R. N. et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 20, 1793240 (2014).
5. Vos, B. et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): A major cause of cryptogenic liver disease. Acta Gastroenterol Belg 74, 38994 (2011).
6. Eguchi, Y. et al. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol 46 Suppl 1, 708 (2011).
7. Petta, S. et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 35, 23847 (2012).
8. Vongsuvanh, R., George, J., McLeod, D. & van der Poorten, D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 57, 3928 (2012).
9. Diez-Rodriguez, R. et al. Insulin resistance and metabolic syndrome are related to non-alcoholic fatty liver disease, but not visceral adiposity index, in severely obese patients. Rev Esp Enferm Dig 106, 5228 (2014).
10. Fracanzani, A. L. et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol 54, 12449 (2011).
11. Das K., C. A. Lean NASH: distinctiveness and clinical implication. Hepatol Int 7, S806S813 (2013).
12. Rinella, M. E. et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49, 106876 (2008).
13. Tanaka, N. et al. Role of white adipose lipolysis in the development of NASH induced by methionine-and choline-deficient diet. Biochim Biophys Acta 1841, 1596607 (2014).
14. Jha, P. et al. Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta 1842, 95970 (2014).
15. Monetti, M. et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 6, 6978 (2007).
16. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40, 14615 (2008).
17. Valenti, L. et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51, 120917 (2010).
18. Shen, J. et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 39, 5329 (2014).
19. Kato, H. et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: Proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci 17, 296304 (2010).
20. Reilly, N. R., Lebwohl, B., Hultcrantz, R., Green, P. H. & Ludvigsson, J. F. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J Hepatol 62, 140511 (2015).
21. Sourianarayanane, A. et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 7, e27985 (2013).
22. Cui, Z., Vance, J. E., Chen, M. H., Voelker, D. R. & Vance, D. E. Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase. A specific biochemical and cytological marker for a unique membrane fraction in rat liver. J Biol Chem 268, 1665563 (1993).
23. Jacobs, R. L. et al. Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity. J Biol Chem 285, 2240313 (2010).
24. Holloway, C. T. & Garfield, S. A. Effect of diabetes and insulin replacement on the lipid properties of hepatic smooth endoplasmic reticulum. Lipids 16, 52532 (1981).
25. Welt, K. et al. Ultrastructural, immunohistochemical and biochemical investigations of the rat liver exposed to experimental diabetes und acute hypoxia with and without application of Ginkgo extract. Exp Toxicol Pathol 55, 33145 (2004).
26. Kanie, T. et al. Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol Cell Biol 32, 590605 (2012).
27. Hanse, E. A. et al. Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4alpha. Cell Cycle 11, 268190 (2012).
28. Matteoni, C. A. et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116, 14139 (1999).
29. Walkey, C. J., Donohue, L. R., Bronson, R., Agellon, L. B. & Vance, D. E. Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase. Proc Natl Acad Sci USA 94, 128805 (1997).
30. Li, Z. et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 3, 32131 (2006).
31. Vance, D. E. Physiological roles of phosphatidylethanolamine N-methyltransferase. Biochim Biophys Acta 1831, 62632 (2013).
32. Wu, G. et al. Choline supplementation promotes hepatic insulin resistance in phosphatidylethanolamine N-methyltransferasedeficient mice via increased glucagon action. J Biol Chem 288, 83747 (2013).
33. Horl, G. et al. Sequential synthesis and methylation of phosphatidylethanolamine promote lipid droplet biosynthesis and stability in tissue culture and in vivo. J Biol Chem 286, 1733850 (2011).
34. Noga, A. A., Zhao, Y. & Vance, D. E. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 277, 4235865 (2002).
35. Fu, S. et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473, 52831 (2011).
36. Unger, R. H. & Orci, L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585, 20212 (2002).
37. Unger, R. H. & Scherer, P. E. Gluttony, sloth and the metabolic syndrome: A roadmap to lipotoxicity. Trends Endocrinol Metab 21, 34552 (2010).
38. Cazanave, S. C. & Gores, G. J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 5, 7185 (2010).
39. Syn, W. K., Choi, S. S. & Diehl, A. M. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 13, 56580 (2009).
40. Jager, R. & Fearnhead, H. O. "Dead Cells Talking": The Silent Form of Cell Death Is Not so Quiet. Biochem Res Int 2012, 453838 (2012).
41. Hamano, M. et al. Lipid overloading during liver regeneration causes delayed hepatocyte DNA replication by increasing ER stress in mice with simple hepatic steatosis. J Gastroenterol 49, 30516 (2014).
42. Ybe, J. A. Novel clathrin activity: developments in health and disease. Biomol Concepts 5, 17582 (2014).
43. Fotin, A. et al. Molecular model for a complete clathrin lattice from electron cryomicroscopy. Nature 432, 5739 (2004).
44. Enari, M., Ohmori, K., Kitabayashi, I. & Taya, Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev 20, 108799 (2006).
45. Endo, Y. et al. Regulation of clathrin-mediated endocytosis by p53. Genes Cells 13, 37586 (2008).
46. Ohmori, K. et al. Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription. Oncogene 27, 221527 (2008).
47. Ohata, H. et al. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation. J Mol Biol 394, 46071 (2009).
48. Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nat Rev Cancer 9, 691700 (2009).
49. Gottlieb, E. & Vousden, K. H. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2, a001040 (2010).
50. Berkers, C. R., Maddocks, O. D., Cheung, E. C., Mor, I. & Vousden, K. H. Metabolic regulation by p53 family members. Cell Metab 18, 61733 (2013).
51. Escobar, G. A., McIntyre, R. C. Jr., Moore, E. E., Gamboni-Robertson, F. & Banerjee, A. Clathrin heavy chain is required for TNFinduced inflammatory signaling. Surgery 140, 26872 (2006).
52. Horie, Y. et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113, 177483 (2004).
53. Dong, H. et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol 46, 91520 (2007).